Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025168 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00025168 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT00025168, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients who have locally advanced, unresectable pancreatic cancer.
Interventions
- RADIATION radiation therapy
- DRUG irinotecan hydrochloride
- DRUG gemcitabine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2001-11-01 |
| Est. Completion | 2003-08-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025168
The ClinicalTrials.gov registry entry for NCT00025168 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which radiation therapy is the first listed.
NCT00025168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025168 about?
NCT00025168 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination...
What is the current status of trial NCT00025168?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2001-11-01. Estimated completion is 2003-08-29.
What interventions are being tested in trial NCT00025168?
The interventions under investigation include: radiation therapy (RADIATION), irinotecan hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00025168?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.